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Strengths and limitations of this study
 ► Review of the literature will ensure that all relevant 
evidence is captured.
 ► A user- centric approach to development will result 
in a decision aid (DA) that addresses the needs of 
patients with motor neuron disease (MND).
 ► Using an iterative process to determine essential 
content for the DA and to develop the prototype may 
be time- consuming.
 ► Allowing patients the option to have a family mem-
ber, friend or carer present during the interviews has 
the potential to influence the honesty and openness 
of their responses.
ABSTRACT
Introduction Motor neuron disease (MND) is a 
progressive, incurable disease, characterised by 
degeneration of the nerves in the brain and spinal cord. 
Due to the multisystem effects of the disease, patients are 
faced with many complex, time- sensitive decisions, one 
of which is the decision on gastrostomy feeding. There 
are currently no published decision aids (DAs) to support 
patients making this decision in the UK. This study will 
develop and pilot a patient DA to provide evidence- based 
information on gastrostomy placement and feeding that is 
relevant to people with MND; communicate the risks and 
benefits associated with each option; check understanding 
and clarify personal values and preferences, enabling 
patients to make a decision congruent with their values 
and appropriate for them.
Methods and analysis A two- phase process, observing 
the International Patient Decision Aid Standards, will be 
used to develop the DA, over 24 months starting January 
2019. Phase 1 will use literature reviews and stakeholder 
interviews and surveys to identify essential content for the 
DA, and explore the best way to present this. In the second 
phase, a prototype DA will be developed and revised using 
stakeholder feedback in an iterative process. Stakeholders 
will include individuals with MND, their carers and the 
healthcare professionals working with them.
Ethics and dissemination Ethical approval for the study 
has been granted by West of Scotland Research Ethics 
Service, reference 19/WS/0078. Study findings will be 
disseminated through academic and non- academic 
publications, conference presentations, stakeholder 
websites and social media. A feasibility study will follow 
to explore the acceptability and practicality of the DA 
for patients, carers and HCPs in practice and to assess 
whether the DA shows promise of being beneficial for the 
intended population.
InTRoduCTIon
Motor neuron disease (MND) is a progressive, 
incurable disease, characterised by degenera-
tion of the nerves in the brain and spinal cord, 
leading to muscle weakness. It is estimated 
that up to 5000 people are living with MND 
at any one time in the UK, with reported inci-
dence rates of 1.06–2.4 per 100 000 people per 
year.1 Typical life expectancy from symptom 
onset is 3 years.2 However, due to the hetero-
geneity of MND, prognosis is unpredictable, 
with some individuals living for many years 
after diagnosis and others far less.3 Patients 
will experience volatile multisystem physical 
deterioration over the course of their disease, 
which may be accompanied by cognitive 
and behavioural change,4 requiring them 
to navigate a challenging care pathway with 
numerous complex decisions.
Dysphagia (difficulty swallowing) is 
common in people with MND. Those with 
bulbar subtypes of the disease will typi-
cally experience dysphagia early on in their 
disease trajectory, with more than two- thirds 
of all people with MND affected in late 
stages of the disease.5 Dysphagia may cause 
distressing coughing and choking, laboured 
mealtimes and aspiration, which in turn can 
lead to recurrent chest infections, nutritional 
decline and weight loss.6
When an individual with MND presents with 
the signs and symptoms of dysphagia, gastros-
tomy tube feeding is often recommended, 
based on the assumption that there will be 
a beneficial impact on nutritional outcome, 
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survival and quality of life (QOL).7 8 Gastrostomy refers 
to the opening made in the abdomen, through which the 
feeding tube enters the stomach, and as with any surgical 
procedure, carries a level of risk. However, there are no 
randomised controlled trials that explore the efficacy of 
tube feeding in MND and results from other research are 
equivocal, weak or lacking with respect to survival, nutri-
tional outcome and QOL, respectively.9
Gastrostomy feeding can have a significant impact on 
an individual’s everyday life, with both positive and nega-
tive consequences.10 Negative impacts include difficulties 
with feed administration, handling the equipment and 
managing supplies and storage, along with potential clin-
ical complications and the psychological impact, such as 
anxiety around the tube and social isolation through loss 
of shared mealtimes. Potential benefits may include relief 
of anxiety associated with prolonged, effortful mealtimes 
by removing the need to eat and drink, weight stabili-
sation and perceived survival benefit. From the patient 
and carer perspective, this means the decision regarding 
whether to have a gastrostomy is not straightforward. To 
add to the complexity, there is also a time sensitivity to 
this decision, which was explored in ProGas,11 a large 
longitudinal prospective cohort study that investigated 
optimum timing and method of gastrostomy for people 
with MND. The study found that while earlier gastrostomy 
may improve survival time and nutritional outcomes, 
some patients might delay placement or not want a 
tube placing at all. This is reflected in current National 
Institute for Health and Care Excellence guidelines for 
MND,12 which state that the role of gastrostomy feeding 
should be discussed at an early stage but that it must be 
recognised that not all individuals will wish to proceed.
While there are some excellent educational resources 
about gastrostomy placement and feeding, including 
‘myTube’, informed by the findings of ProGas11 and 
online information provided by the MND Association,13 
there are no published patient decision aids (DAs) for 
this group in the UK. DAs are designed to do more 
than to provide information; they are usually developed 
for complex, preference- based decisions that require 
greater consideration.14 These decisions will often have 
multiple options with features or outcomes that people 
value differently, in this case undergoing gastrostomy 
placement, deciding against gastrostomy or deciding to 
revisit the issue at a later date. Often the evidence base 
for each option is limited and so the best choice depends 
on the personal importance the individual places on the 
benefits, harms, burden and scientific uncertainties.14 
By presenting evidence- based information, communi-
cating the risks and benefits associated with each option, 
checking understanding and clarifying personal values 
and preferences, a DA may help individuals with MND 
make a decision about whether a gastrostomy is congruent 
with their values and appropriate for them.15 They can also 
provide an outline for conversations with family members 
and healthcare professionals (HCPs) and encourage a 
collaborative approach to decision- making.16 It is crucial 
to acknowledge the importance of involving close family 
members and carers in the gastrostomy decision- making 
process. Research has shown that carers may directly or 
indirectly influence patient decision- making and that 
patients often want to share the burden of decision- 
making with family and carers,17 in some cases relying 
on the carer or family member in order to participate in 
the decision- making process.18 For individuals with MND, 
communication difficulties secondary to their disease 
may augment their reliance on carers or family members. 
While the values and preferences of the patient must take 
priority, developing a DA that includes content for carers 
ensures that these individuals are well informed and 
able to participate fully in discussions, thus offering the 
patient better support in the decision- making process. It 
also provides support for the carer themselves, allowing 
them to prepare for the potential impact of the patient’s 
decision on their own lives and providing signposting to 
further support and information.
The development of a DA to support shared decision- 
making aligns with current NHS priorities of patient- 
centred, value- based healthcare. Shared decision- making 
is a key component of NHS England’s personalised care 
approach, laid out in their Universal personalised care 
model,19 20 as part of the Long Term Plan.21 The model 
is underpinned by the evidence that shared decision- 
making leads to more realistic expectations, a better 
match between individuals’ values and treatment choices 
and fewer unnecessary interventions.20 NHS Rightcare’s 
value- based initiative22 also highlights the importance of 
listening to patients to identify what is of value to them 
to ensure that their care ‘delivers’ on an individual level, 
and using this to design and deliver services accordingly. 
The DA will support these NHS approaches by empow-
ering the patient to participate in shared decision- making 
regarding gastrostomy placement.
The study will answer the following research questions:
1. What information should be included in a DA for 
people with MND considering whether to have a gas-
trostomy, their carers and HCPs, and how is this best 
presented?
2. Do people with MND, carers and HCPs find a web- 
based DA easy to use and useful?
METhodS And AnAlySIS
This research protocol details the process for the devel-
opment and piloting of a DA for individuals with MND, 
deciding whether to have a gastrostomy tube for feeding. 
The study will be conducted over 24 months and started 
in January 2019.
The study will have two phases:
Phase 1: will address the first research question by inves-
tigating what information should be included in the DA 
and how this is best presented.
Phase 2: the prototype DA will be developed, and the 
second research question will be addressed by exploring 
whether the prototype DA is easy to use and useful to the 
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Table 1 Patient and carer sampling frame
<6 months since diagnosis >6 months since diagnosis
Gastrostomy Aim to recruit where possible Interview: patients n=10, carers n=5
Beta- testing: patients n=3–4, carers n=3–4
No gastrostomy Interview: patients n=10, carers n=5
Beta- testing: patients n=3–4, carers n=3–4
Interview: patients n=10, carers n=5
Beta- testing: patients n=3–4, carers n=3–4
The amber cell is highlighted and discussed in the text below to recognise that the number of particpants recruited in this group is likely to be 
small.
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Individuals with a confirmed diagnosis of MND with a life 
expectancy of at least 1 year as reported by the clinical team
OR
Carers, defined as ‘Any adult who looks after a family 
member, partner or friend with MND. The care they give is 
unpaid, and they have face- to- face contact with the person 
with MND at least 3 times a week’ (currently or within the last 
year). They may or may not be in receipt of carers allowance
OR
Healthcare professionals working with individuals with MND, 
involved in the gastrostomy decision- making process or 
supporting patients with gastrostomy feeding
AND
Able to communicate, either verbally or using other means, for 
example, using a communication aid, at phrase or sentence 
level
Unable to participate in English
<18 years
Individuals assessed as lacking capacity by the clinical team
Carers of individuals assessed as lacking capacity
MND, motor neuron disease.
end user(s). Usefulness is defined in terms of whether it 
meets users’ needs, attitude towards using it and perceived 
benefit.
This will be followed by a multicentre feasibility study 
(phase 3) to explore the acceptability and practicality of 
the DA for patients, carers and HCPs in practice, and to 
assess whether the DA shows promise of being benefi-
cial for the intended population. Details of which will be 
presented in a later publication.
Participants
Participants will include individuals from the three key 
stakeholder groups involved in the decision- making 
process: individuals living with MND (patients), their 
carers and the HCPs working with them.
Purposive sampling23 will be employed to optimise 
stakeholder representation, ensuring the DA content 
meets the needs of the UK MND population. The 
sampling frame will be based on time since diagnosis 
and gastrostomy placement (table 1). Those participants 
in the ‘no gastrostomy’ group will include patients who 
have declined gastrostomy. A similar number of partici-
pants will be sought in each of the green cells. Although 
recruitment of patients and carers in the amber cell will 
be attempted, it is anticipated that the number of patients 
and carers who fall into this group will be small.
We aim to recruit patients who are broadly representa-
tive of the MND population in terms of age, gender and 
subtype of MND and we will include both people who 
currently live alone and those who live with others. HCPs 
will be drawn from a variety of professions including 
doctors, nurses and allied health professionals.
Inclusion and exclusion criteria will be applied to poten-
tial participants (table 2). The clinical care team will be 
consulted to confirm whether the individual has capacity 
to provide informed consent. Individuals assessed as 
lacking capacity and their carers will be excluded because 
their decision- making informational needs are likely 
to differ significantly from those with capacity. Future 
research should investigate the needs of individuals with 
MND lacking capacity, and their care network, in gastros-
tomy decision making.
design
The methods for the two phases of the study are based 
on a validated model for web- based DAs24 and the orig-
inal 2005 International Patient Decision Aid Standards 
(IPDAS),25 and will observe the Medical Research Coun-
cil’s guidance for the development of complex interven-
tions.26 Phase 1 of the study will elicit the information 
that should be included in the DA and identify the best 
way to present it. In phase 2, the DA will be developed 
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and revised. A study advisory committee (SAC) including 
individuals living with MND, their carers and HCPs and 
researchers with experience in MND and/or patient 
decision- making has been assembled and has contributed 
to the study design.
Phase 1: Content and presentation
Literature reviews
A literature review to identify qualitative studies that 
explore the informational needs of people with neuro-
degenerative disease considering a gastrostomy will be 
conducted using standard methods.27 The search will be 
limited to decision- making around gastrostomy, rather 
than including all healthcare decisions for this group, 
primarily because of the invasive nature of the proce-
dure. The search will also be limited to studies of patients 
with neurodegenerative disease, rather than any condi-
tion where tube feeding may be offered, because of the 
parallels with MND experience and disease outcomes. 
Thematic analysis will be used to identify information 
that is valued when decision- making.
A second literature review will identify theories that 
could be used to underpin the DA and also the best 
methods for presenting information within the context 
of a web- based DA. This review will search for web- based 
DAs and studies describing their development and eval-
uation, both for patients with MND and other patient 
groups. Methods for presenting information will be tabu-
lated, along with any information about efficacy. Infor-
mation about the theoretical underpinning of DAs will 
also be collated to help with the selection of a theory to 
underpin the DA and to identify the active ingredients 
of the decision- making process. Final theory selection 
will be driven by the findings from the interviews. For 
example, if people want to get the 'gist' in the first layer 
of information, then delve deeper for more detail at their 
discretion, the Fuzzy Trace Theory28 may be applied. The 
intention is to publish both literature reviews in a sepa-
rate publication(s).
Interviews
Cross- sectional, semi- structured in- depth interviews with 
patient, carer and HCP participants will explore rele-
vant personal experiences (individuals and carers only); 
important information to include when making a decision 
about whether to have a gastrostomy; what a DA might 
look like and when and how a DA should be introduced. 
The informational needs of carers supporting individuals 
to make this decision will also be investigated. An inter-
view guide, developed with support from the SAC, will be 
used to guide but not to constrain the interviews. Inter-
views will be carried out either in person or by telephone, 
at a time and place convenient to the participant. Inter-
views will be audio recorded and transcribed verbatim. 
It is recognised that a significant proportion of patient 
participants will have communication difficulties.29 To 
minimise the burden of the interviews for patients, they 
will be sent the interview guide ahead of the interview, to 
allow them to begin to construct their answers. Patients 
may respond verbally or by using an alternative form of 
communication. This may include electronic communi-
cation devices, such as a smartphone or tablet device,30 or 
in writing (e.g. in person or via email). Patient and carer 
interviews will be conducted independently, although 
patient participants will be able to have a family member, 
friend or carer present in the interview if preferred.
Clinical (patients only) and demographic data will 
also be collected, during or prior to the interview, to 
allow description of the study sample and evaluation of 
whether it is representative of a typical MND population 
in the United Kingdom. Patient data will be obtained 
from medical notes, while demographic data from carers 
and HCPs will be reported by the participant. This will 
include:
Patients: age, gender, ethnicity, level of education, 
employment status, domestic status, family history of 
MND, date of diagnosis, type of MND, site of onset, stage 
of disease, gastrostomy placed (yes or no, date if appli-
cable and why).
Carers: age, gender, ethnicity, level of education, 
employment status, family history of MND.
HCPs: years qualified, job title, time working in the 
field of MND.
Sample sizes for the interviews were chosen based on 
previous similar projects that have achieved data satura-
tion with these sample sizes.31 We will evaluate this assump-
tion during the analysis phase by checking that the final 
three interviews did not generate any new themes, if this 
criterion is not met we will continue to carry out inter-
views until it is met.32
DA content
Interview and literature review outputs will be synthesised 
using a framework analysis approach.33 One researcher 
(RM) will code each transcript, line by line, with a second 
researcher (SW) independently coding 10% of the tran-
scripts. The coding system will be harmonised through 
discussion and the agreed coding system will then be 
applied to the whole data set, with refinement as needed. 
Themes will be identified by grouping together similar 
codes. The coding system, along with the themes iden-
tified from the transcripts and the first literature review, 
will also be discussed with the SAC and modified if neces-
sary, until consensus is reached. NVivo 12 will be used for 
data management.
The identified themes will be presented in a survey as 
pieces of information which could be included in the DA. 
The survey will be sent to the participants who were inter-
viewed, as well as members of the SAC and study team, 
who all will be asked to prioritise each suggested piece 
of content using the prioritisation model MoSCoW.34 For 
each piece of content, respondents will be asked to rate 
how crucial it is for this to be included in the DA (M—
Must have; S—Should have; C—Could have; W—Would 
like if time permits). Respondents will choose whether to 
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complete the survey online, on a hard copy or over the 
telephone.
Finally, a systematic search of the evidence base relating 
to each suggested piece of content will be carried out to 
ensure all information included in the DA is accurate. 
The search will include published papers, guidelines, best 
practice documents, other grey literature and input from 
clinical experts on the SAC.
Phase 2: Prototype development and piloting of the dA
Results from phase 1 will inform the development of the 
prototype DA. The SAC and research team will use the 
findings from the interviews to select the relevant theory 
from those identified in the literature review to underpin 
the DA. The SAC and research team will develop a proto-
type DA, using an iterative process, by incorporating each 
piece of information receiving the highest prioritisation 
scores in phase 1 survey and observing the 2005 IPDAS 
checklist.25 The IPDAS checklist details required content 
to ensure that information about options is presented 
with sufficient detail for decision- making, that informa-
tion is presented in an unbiased and understandable way 
and that methods for clarifying and expressing patients’ 
values are included, along with tools to support making 
the actual decision and communicating this decision to 
others.
The DA will be web- based, programmed using respon-
sive web design, enabling use on tablets, laptops and 
smart phones. The prototype will then undergo alpha 
testing, where phase 1 study participants will review the 
prototype and complete a survey to provide feedback on:
1. Clarity of prototype information.
2. Presentation and functionality of prototype informa-
tion (user- friendliness and acceptability).
3. Perceptions of utility.
It is recognised that between the interview and alpha 
testing (expected time frame of 3–8 months depending 
on when the participant is recruited), a proportion of 
patient participants may become too unwell to partici-
pate or will die. The period between interview and alpha 
testing will be kept as short as possible; however if a 
patient is unable to participate in the alpha testing, this 
will be treated as missing data.
Feedback will be discussed with the SAC and a second 
version of the prototype DA will then be produced. 
Version 2 will undergo beta testing; newly recruited 
patients, carers and HCPs (n=5 of each) will talk through 
their use of the DA following the ‘think aloud’ method.35 
A think aloud interview guide will be used to prompt 
participants to verbalise their thoughts as they use the 
DA, allowing the assessment of usability, satisfaction and 
acceptability.35 Immediately after this, evaluation ques-
tions will be used to ascertain users’ attitudes towards 
using the DA, whether it meets their needs and whether 
they think it is of benefit.
The SAC and study team will then meet again to review 
the results and produce version 3 of the prototype, which 
will undergo beta testing with a new set of participants 
(n=5 of each group). Finally, the SAC and study team will 
decide whether any additional changes are required and 
the final prototype will be produced.
The formal evaluation of the DA will take place in 
phase 3, the details of which will be presented in a subse-
quent publication. In brief, the DA will be used in clinical 
settings. An evaluation framework, comprising measures 
of both the quality of the decision- making process and 
the quality of the decision itself, will be developed and 
used to compare the outcomes of patients who use the 
DA and those who do not. This will be supplemented with 
semi- structured interviews with stakeholders to explore 
acceptability and practicality of the DA, and to provide 
insight into implementation.
Recruitment
Patient and carer participants will be identified by a 
member of their clinical care team in NHS MND and 
palliative care clinics across the Wessex and Sheffield 
regions. Permission will be obtained to share the contact 
details of any individual interested in participating, with 
the research team. Support groups, such as those run by 
the Motor Neurone Disease Association (MNDA), will 
provide another avenue for the recruitment of patients 
and carers. A member of the research team will attend 
the local support group in person to introduce the 
study, provide a participant information sheet to those 
interested in participating and request permission to 
make follow- up contact. A third channel for patient and 
carer recruitment will be advertisements placed on rele-
vant websites and social media platforms, for example, 
Twitter. Interested individuals will be invited to contact 
the researcher, who will provide a participant information 
sheet and request permission to make follow- up contact. 
The clinical care team will be consulted to confirm the 
eligibility of all patient participants.
Eligible HCPs will be identified either following direct 
approach by the researcher, via a member of the advisory 
committee (who will obtain consent to share their contact 
details with the researcher), or through advertisements 
via social media and professional groups. A researcher 
will discuss the study with the individual, provide a partic-
ipant information sheet and request permission to make 
follow- up contact.
All participants will be asked to provide informed 
consent prior to participation in the study.
Patient and public involvement
People living with MND and their carers will be involved 
throughout the research process. The idea of developing 
a DA for people with MND considering a gastrostomy was 
initially presented to an MND support group for feedback 
and to invite members to join the research team.
Following award of the grant, people living with MND 
and their carers have joined the SAC; through this, they 
will help prioritise content for the DA, evaluate each iter-
ation of the DA and comment on all patient and carer 
facing study documents. They will also advise on the 
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practicalities of including people with MND as research 
participants and have input on the recruitment strategy.
The views and insights of patient and carer participants 
will be central to the research and will form the majority 
of the study sample. Participants will be asked whether 
they wish to be kept up to date with the project’s progress 
and those who do will be sent a newsletter.
Consent
The researcher will obtain written informed consent 
from participants before entering into the study. For 
patient participants, this will include seeking permission 
to inform their general practitioner of their participation 
in the study. In the case that the individual is unable to 
provide written consent, consent will be indicated by the 
participant answering ‘yes’ or ‘no’, either verbally or via 
a communication device, after each statement on the 
consent form. The form will then be signed by the parties 
involved in the consent conversation.36
Given the sensitive nature of the topics to be discussed, 
the researcher will make clear that participation is volun-
tary, and the right to ask any questions and to decline 
participation at any time will be highlighted during the 
data collection.
Participant confidentiality
The study will adhere to the principles of Good Clinical 
Practice and in accordance with current Data Protec-
tion Regulations, the General Data Protection Act 2018 
(GDPR) and all other regulatory requirements, as appro-
priate. Necessary steps will be taken to ensure that all data 
remain confidential at all times. Study data will be kept 
for 10 years from the end of the study, in accordance with 
University of Southampton policy. Only members of the 
research team will have access to the full data set.
dissemination
A dissemination and impact plan will be developed in 
the initial stages of the study. Dissemination will be led by 
working collaboratively with Marie Curie and the MNDA 
(the Funders) and Public Policy, University of South-
ampton, to develop and take forward the impact activities 
to ensure maximum publicity and benefit. Study findings 
will be disseminated via multiple channels, including 
peer- reviewed academic publications, non- academic 
publications, conference presentations, stakeholder 
websites and social media. All participants will be notified 
of the outcome of the study by newsletter, press release 
and infographic.
Once a final prototype has been developed, a multi-
centre feasibility study will be carried out to explore the 
acceptability and practicality of the DA for patients, carers 
and HCPs in practice, and to assess whether the DA shows 
promise of being beneficial for the intended population. 
The protocol for the feasibility study will be presented 
in a subsequent publication. On completion of the feasi-
bility study, it is anticipated that there will be a DA that 
can be used in clinical practice with the aim of improving 
the decision- making process and quality of decision for 
individuals with MND deciding whether to have a gastros-
tomy. It is also hoped that national and regional MND 
guidelines will make reference to the tool. The project 
therefore has the potential for multifaceted impact by 
advancing patient care, improving service delivery and 
providing useful insights for the development of DAs in 
the future.
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